Table 2. Clinical, laboratory, and neuroimaging findings for patients with Miller Fisher syndrome.
| Neurological complication | Value (n=11) |
|---|---|
| Hyporeflexia/areflexia | 11 (100.0) |
| Ataxia | 10 (90.9) |
| Extraocular muscle paresis | 9 (81.8) |
| Diplopia | 9 (81.8) |
| Sensory symptoms | 8 (72.7) |
| Weakness of facial muscles | 6 (54.5) |
| Eyelid ptosis | 4 (36.4) |
| Dysphonia/dysarthria | 3 (27.3) |
| Autonomic dysfunction | 3 (27.3) |
| Motor weakness | 3 (27.3) |
| Nystagmus | 2 (18.2) |
| Tongue deviation | 2 (18.2) |
| Dysphagia | 2 (18.2) |
| MRI alterations* (n=9) | 1 (11.1) |
| AIDP pattern in NPS (n=5) | 4 (80.0)† |
| Albuminocytological dissociation in the CSF analysis (n=9) | 7 (77.8) |
| Positivity for SARS-CoV-2 RNA in CSF (n=5) | 0 (0.0) |
| Presence of antiganglioside antibodies (n=9) | 2 (22.2) |
| Treatment with IVIg | 10 (90.9) |
| Death | 1 (9.1) |
Data are presented as n (%).
*Enhanced T2-weighted hyperintensity and enlargement of the oculomotor nerve; †One neurophysiological study showed a slight F-wave delay in the upper limbs, without peripheral demyelination or axonal damage. AIDP, acute inflammatory demyelinating polyneuropathy; CSF, cerebrospinal fluid; IVIg, intravenous immunoglobulin; MRI, magnetic resonance imaging; NPS, neurophysiological study; SARS-CoV-2, severe acute respiratory syndrome coronavirus 2.